The efficacy of switching basal-bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching.
Toshihito AndoMasaki KondoYuriko Asada-YamadaMiyuka KawaiEmi Asano-HayamiTomohide HayamiMikio MotegiYohei EjimaEriko NagaoRina KasagiHiromi Nakai-ShimodaSaeko AsanoMakoto KatoYuichiro YamadaEmiri Yura-MiuraTakahiro IshikawaYukako Sugiura-RothChika KojimaEna NaitoTatsuhito HimenoShin TsunekawaYoshiro KatoJiro NakamuraHideki KamiyaPublished in: Diabetology international (2023)
The efficacy of BOT with mitiglinide/voglibose depended on residual insulin secretory abilities. This therapy would be a useful therapeutic option for patients with type 2 diabetes.